Bayer’s New Study on Nifurtimox: Implications for Investors

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Bayer AG has initiated an observational pregnancy safety study titled Observational Pregnancy Safety Study of Women Exposed to Nifurtimox During Pregnancy to Describe the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant. The study aims to assess the safety of nifurtimox, a drug used for over 50 years to treat Chagas disease, in pregnant women and its potential effects on their babies. This research is significant as there is currently insufficient data on the drug’s safety during pregnancy.

The intervention being tested is the drug Nifurtimox (BAYA2502). It is administered to pregnant women to evaluate its impact on fetuses, neonates, and infants up to 12 months of age, as well as any maternal complications during pregnancy.

The study is observational with a cohort model and a prospective time perspective. It does not involve any allocation or masking, focusing instead on collecting data from women exposed to nifurtimox during pregnancy to compare with general population outcomes.

The study is set to start on December 31, 2025, with an estimated duration of approximately 10 years. The primary completion and estimated completion dates have not been specified, but the last update was submitted on July 25, 2025. These dates are crucial for tracking the study’s progress and potential findings.

For investors, this study could influence Bayer’s stock performance and investor sentiment, especially if the findings impact the use of nifurtimox in new markets or patient demographics. The study’s outcome might also affect Bayer’s competitive standing in the pharmaceutical industry, particularly in treatments related to Chagas disease.

The study is ongoing, with further details available on the ClinicalTrials portal.